Methicillin-resistant Staphylococcus Aureus Drugs Market size was over USD 4.24 billion in 2024 and is poised to exceed USD 7.33 billion by 2037, growing at over 4.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of methicillin-resistant staphylococcus aureus drugs is evaluated at USD 4.39 billion.
The growth of the market is attributed to the growing prevalence of MRSA infection worldwide. A total of 119 studies with 164,717 participants from 29 different nations were determined to be suitable for meta-analysis. This meta-analysis represented that MRSA was present in 14.69% of cases globally. Therefore, the demand for medication for the MRSA infection is growing which is further estimated to boost the market.
Furthermore, the most prevalent kind of staphylococcus infections involve those that affect the skin and soft tissues. The frequency of skin and soft tissue infections has increased as a result of an increasing number of antimicrobial medication failures in outpatient treatment. Thus, one of the main factors influencing market growth throughout the projected period is the increased prevalence of staphylococcal infections.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.3% |
|
Base Year Market Size (2024) |
USD 4.24 billion |
|
Forecast Year Market Size (2037) |
USD 7.33 billion |
|
Regional Scope |
|
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
In methicillin-resistant staphylococcus aureus drugs market, hospital pharmacy segment is poised to dominate around 50% share by the end of 2037. This could be owing to the rising number of hospitals in this region. The total number of hospitals around the globe as of 2021 is projected to be about 164,000. Furthermore, hospitals are the exclusive partners with hospital-based reference laboratories for methicillin-resistant staphylococcus aureus drugs.
Due to the huge volume of patients, lengthy turnaround times, and high costs associated with hospitals, only a small number of complex tests are referred to these laboratories. These labs use skilled laboratory professionals and state-of-the-art equipment to handle the large volume of tests. Clinical research, disease surveillance programs, monitoring response to treatment, and disease diagnosis all depend significantly on hospitals and diagnostic labs.
Timely and timely intervention is made feasible by diagnostic techniques, which lowers the impact of disease and improves health. The medication needed for MRSA is determined using the information gathered from patient samples. As a result, the segment will have steady growth in methicillin-resistant staphylococcus aureus drugs market.
Drug Class (Lipopeptide, Oxazolidine, Tetracycline, Cephalosporin, Lipoglycopeptide, Folate Antagonist
In methicillin-resistant staphylococcus aureus drugs market, lipopeptide segment is estimated to capture over 30% revenue share by 2037. This may be due to lipopeptides including daptomycin that have a well-established market due to effective global distribution by producers and distributors. Newly developed lipopeptide antibiotic daptomycin is bactericidal against a variety of gram-positive isolates when delivered intravenously.
It exhibits quick, dependent on concentration bactericidal action against isolates that are vulnerable, such as MRSA. Although complex urinary tract infections are also treated with it, gram-positive bacterial skin and soft tissue infections are the main indications for its usage.
Our in-depth analysis of the Global Market Includes the following segments:
|
Drug Class |
|
|
Administration |
|
|
Distribution Channel |
|
North America Market Statistics
By 2037, North America Region is expected to account for around 40% methicillin-resistant staphylococcus aureus drugs market share. This growth is set to be influenced by rising COVID-19 cases. At this point in Northern America, the new coronavirus has been responsible for at least over 93,186,000 recorded infections and about 1,065,000 documented deaths.
Multiple manufacturing facilities in the United States were forced to close as a consequence of the COVID-19 outbreak. Nonetheless, since COVID-19 patients require more stringent hygienic measures, the outbreak assisted in the local methicillin-resistant staphylococcus aureus drugs business expansion. Methicillin-resistant staphylococcus aureus drugs suppliers have to boost production in response to the pandemic to keep up with the rising demand. This is in addition to the fact that one of the regions in the market under study with the quickest growth is North America.
Additionally, throughout the projected period, the United States is projected to dominate the global market. The primary source of this share of the market is the funding provided by American businesses for the investigation and creation of instruments for evaluating MRSA infection.
European Market Analysis
The European region will also encounter huge growth for the methicillin-resistant staphylococcus aureus drugs market during the forecast period. For the reduction of the prevalence of surgical site infections (SSIs) in the country, the UK government has initiated major actions. One of the most prevalent types of infections connected with hospital settings is surgical site infection (SSI) which is a type of infection that falls under the category of Healthcare-Associated Infections (HAIs).
These SSIs occur in the post-surgery area and are linked to increased attributable morbidity & mortality, longer hospital admissions following surgery, the need for further surgical procedures, and the need for critical care. All-inclusive, the European market for methicillin-resistant staphylococcus aureus (MRSA) is experiencing expansion as a result of the government's increased efforts and preventive measures to control surgical site infections.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?